cUTI is responsible for high morbidity and mortality1

~75% of ICU-associated UTIs are due to Gram-negative bacteria2
Most carbapenem-resistant Enterobacteriaceae infections involve the urinary tract3
~40% of nosocomial severe sepsis cases are caused by UTIs and infections of the urogenital tract4
Mortality from urosepsis ranges from 25%-60%5

Rising antibacterial resistance poses a serious challenge to treating cUTI6,7

Priority 1 critical stamp alert for World Health Organization priority pathogen list need for new antibiotics

World Health Organization global priority pathogens list: Top needs for new and effective antibiotics6

Pseudomonas aeruginosa bacterium

Pseudomonas aeruginosa


Acinetobacter baumannii bacteria

Acinetobacter baumannii


Enterobacteriaceae bacteria


carbapenem-resistant, 3rd-generation cephalosporin-resistant

a Enterobacteriaceae include: Klebsiella pneumoniae, Escherichia coli, Enterobacter spp, Serratia spp, Proteus spp, Providencia spp, and Morganella spp.

The CDC, in its 2019 Antibiotic Resistance Threats report, lists carbapenem-resistant Acinetobacter and Enterobacteriaceae as urgent public health threats, and multidrug-resistant P aeruginosa as a serious threat7

Stenotrophomonas maltophilia bacteria

The non-fermenter Stenotrophomonas maltophilia is also an emerging pathogen8

  • Treatment is made more difficult by intrinsic antibacterial resistance to β-lactams, polymyxins, and many other classes of antimicrobials

Antibacterial resistance in cUTI can make a challenging infection even more difficult to treat